ECTRIMS 2022

SISTER–Subcutaneous: Non-interventional, observational, prospective, German multicenter, open label study over 12 months for Tysabri Patient Preference Experience from Real World –Preliminary results of the 1stinterim analysis

Natalizumab-treated RRMS Patients with Prior DMT Use Report Better Outcomes, Treatment Satisfaction, and Unique Benefits than Similar Patients Treated with Ocrelizumab

Exploratory Magnetic Resonance Imaging Endpoints from NOVA: A Randomised Controlled Study of the Efficacy of 6-week Dosing of Natalizumab vs Continued 4-week Treatment for Multiple Sclerosis
